Citi Sets $233 Target for Becton Dickinson, Cites MedTech Focus

Citi's Bullish Stance on Becton Dickinson

Citi has resumed coverage on Becton Dickinson with a Buy rating, setting a price target of $233 for the company's stock. The positive outlook is driven by the strategic sale of its Life Sciences Bioprocessing unit, a move anticipated to enhance the company's focus and growth trajectory.

Situational Overview: A Strategic Shift

The divestment, which is scheduled to be finalized by February 9, 2026, is a key move to reshape Becton Dickinson into a dedicated medical technology business. This new structure will allow the company to concentrate its operations across four core areas: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. This strategic narrowing of focus is expected to provide clearer growth prospects and streamline operations.

Impact on the Market

The transition to a pure-play MedTech company is viewed by Citi as a significant positive catalyst. This strategic clarity is expected to attract investors looking for focused growth in the medical technology sector. The $233 price target suggests strong confidence in the company's future performance and its ability to generate value following the divestment.

Summary and Outlook

Becton Dickinson's sale of its bioprocessing unit marks a pivotal transformation into a more focused MedTech entity. This move has earned a bullish rating from Citi, signaling confidence in the company's streamlined strategy and future growth potential as the 2026 completion date approaches.

FAQ

Q: Why did Citi issue a Buy rating for Becton Dickinson?
A: Citi's Buy rating is based on Becton Dickinson's sale of its Life Sciences Bioprocessing unit, which repositions it as a more focused MedTech company with clearer growth prospects.

Q: What is the new price target for Becton Dickinson?
A: Citi has set a price target of $233 per share for Becton Dickinson.

Q: What will Becton Dickinson's business focus on after the sale?
A: After the sale, Becton Dickinson will operate as a pure-play MedTech company focused on Medical Essentials, Connected Care, Biopharma Systems, and Interventional sectors.

Source: Investing.com